SMFR
Sema4 Holdings Corp. [SMFR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SMFR Stock Summary
In the News
Sema4: Restructuring Plan Figures Don't Add Up
Sema4's restructuring plan has a number of potential downsides that could affect the company's cash position in the coming few quarters. The booting of the CEO signals the start of a strategic focus on short-term survival away from long-term growth.
Sema4 Holdings Corporation (SMFR) Q3 2022 Earnings Call Transcript
Sema4 Holdings Corporation (NASDAQ:SMFR ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Joel Kaufman - VP, Finance & Corporate Development Katherine Stueland - CEO & Director Kevin Feeley - SVP, Operations & CFO Conference Call Participants Mark Massaro - BTIG David Delahunt - Goldman Sachs Operator Welcome to the Sema4 Third Quarter 2022 Earnings Conference Call. My name is Cheryl, and I will be your operator for today's call.
Why Sema4 Holdings Stock Is Crashing Today
The healthcare company delivered plenty of bad news in its Q2 update.
Sema4 Holdings Corp (SMFR) CEO Katherine Stueland on Q2 2022 Results - Earnings Call Transcript
Sema4 Holdings Corp (NASDAQ:SMFR ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Joel Kaufman - VP, Finance & Corporate Development Katherine Stueland - CEO & Director Kevin Feeley - SVP, Operations and Head of GeneDx Conference Call Participants David Delahunt - Goldman Sachs Group Matt Kim - Jeffrey Max Masucci - Cowen and Company Mark Massaro - BTIG Operator Good day, and thank you for standing by. Welcome to the Sema4 Second Quarter 2022 Earnings Conference Call.
Sema4 Holdings, Big Data For Precision Medicine Solutions
Big data and machine learning are booming also in healthcare, where it enables precision medicine and population health platform services. Sema4 Holdings has amassed huge amounts of medical data and a sophisticated platform in order to extract valuable insight from these for health systems, pharma companies and individuals.
Sema4 Holdings Corp. (SMFR) Moves to Buy: Rationale Behind the Upgrade
Sema4 Holdings Corp. (SMFR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sema4 Holdings Corp. (SMFR) CEO Katherine Stueland on Q1 2022 Results - Earnings Call Transcript
Sema4 Holdings Corp. (NASDAQ:SMFR ) Q1 2022 Earnings Conference Call May 13, 2022 4:30 PM ET Company Representatives Katherine Stueland - Chief Executive Officer Eric Schadt - Founder, President and Chief R&D Officer Isaac Ro - Chief Financial Officer Joel Kaufman - Vice President of Finance and Corporate Development Conference Call Participants Mark Massaro - BTIG Max Masucci - Cowen and Company Dave Delahunt - Goldman Sachs Operator Good day! And thank you for standing by.
Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q4 2021 Results - Earnings Call Transcript
Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q4 2021 Results - Earnings Call Transcript
Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition
Sema4 Holdings Corp (NASDAQ: SMFR) has agreed to acquire OPKO Health Inc's (NASDAQ: OPK) wholly-owned subsidiary, GeneDx Inc, for approximately $623 million. Sema4 will acquire GeneDx for an upfront payment of $150 million in cash plus 80 million shares in Sema4, with up to an additional $150 million revenue-based milestones over the next two years.
Sema4 Stock (SMFR): Why The Price Jumped
The stock price of Sema4 Holdings Corp (NASDAQ: SMFR) increased by 13.63% in the most recent trading session. This is why it happened.
SMFR Financial details
SMFR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2020-12-31 | 2021-12-31 |
|---|---|---|---|
| Revenue per share | 0 | 0.88 | |
| Net income per share | 0 | -1.02 | |
| Operating cash flow per share | 0 | -0.79 | |
| Free cash flow per share | 0 | -0.88 | |
| Cash per share | 1.85 | 1.67 | |
| Book value per share | 0.02 | 1.62 | |
| Tangible book value per share | 1.78 | 1.62 | |
| Share holders equity per share | 0.02 | 1.62 | |
| Interest debt per share | 0 | 0.15 | |
| Market cap | 2.65B | 1.07B | |
| Enterprise value | 2.65B | 703.53M | |
| P/E ratio | -13.79K | -4.37 | |
| Price to sales ratio | 0 | 5.05 | |
| POCF ratio | 0 | -5.63 | |
| PFCF ratio | 0 | -5.07 | |
| P/B Ratio | 530.34 | 2.76 | |
| PTB ratio | 530.34 | 2.76 | |
| EV to sales | 0 | 3.32 | |
| Enterprise value over EBITDA | -13.79K | -3.19 | |
| EV to operating cash flow | 0 | -3.69 | |
| EV to free cash flow | 0 | -3.33 | |
| Earnings yield | 0 | -0.23 | |
| Free cash flow yield | 0 | -0.2 | |
| Debt to equity | 3.12 | 0.43 | |
| Debt to assets | 0.04 | 0.3 | |
| Net debt to EBITDA | 5.69 | 1.67 | |
| Current ratio | 14.12 | 4.77 | |
| Interest coverage | 0 | -157.37 | |
| Income quality | 0 | 0.78 | |
| Dividend Yield | 0 | 0 | |
| Payout ratio | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.97 | |
| Research and developement to revenue | 0 | 0.5 | |
| Intangibles to total assets | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.11 | |
| Capex to revenue | 0 | -0.1 | |
| Capex to depreciation | 0 | -0.95 | |
| Stock based compensation to revenue | 0 | 1.03 | |
| Graham number | 0.02 | 6.09 | |
| ROIC | -0.55 | 1.53 | |
| Return on tangible assets | 0 | -0.44 | |
| Graham Net | 1.78 | 1.13 | |
| Working capital | 1.27M | 382.26M | |
| Tangible asset value | 428.54M | 388.1M | |
| Net current asset value | -14.22M | 317.55M | |
| Invested capital | 0 | 0.08 | |
| Average receivables | 0 | 13.28M | |
| Average payables | 0 | 22.35M | |
| Average inventory | 0 | 16.73M | |
| Days sales outstanding | 0 | 45.69 | |
| Days payables outstanding | 0 | 71.3 | |
| Days of inventory on hand | 0 | 53.37 | |
| Receivables turnover | 0 | 7.99 | |
| Payables turnover | 0 | 5.12 | |
| Inventory turnover | 0 | 6.84 | |
| ROE | -0.04 | -0.63 | |
| Capex per share | 0 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0.24 | 0.22 | 0.15 | 0.22 | |
| Net income per share | 0 | -0.17 | -0.32 | -0.76 | -0.2 | |
| Operating cash flow per share | -0.74 | -0.22 | -0.34 | -0.35 | -0.23 | |
| Free cash flow per share | -0.76 | -0.25 | -0.34 | -0.36 | -0.24 | |
| Cash per share | 0 | 1.66 | 1.3 | 1.18 | 0.5 | |
| Book value per share | 0 | 1.61 | 1.36 | 2.64 | 1.47 | |
| Tangible book value per share | 0 | 1.61 | 1.36 | 1.09 | 0.5 | |
| Share holders equity per share | 0 | 1.61 | 1.36 | 2.64 | 1.47 | |
| Interest debt per share | 0 | 0.14 | 0.31 | 0.33 | 0.21 | |
| Market cap | 1.41B | 1.08B | 741.38M | 304.28M | 334.12M | |
| Enterprise value | 1.41B | 709.33M | 499.93M | 98.19M | 220.74M | |
| P/E ratio | 0 | -6.66 | -2.41 | -0.41 | -1.08 | |
| Price to sales ratio | 0 | 18.63 | 13.74 | 8.41 | 4.01 | |
| POCF ratio | -10.25 | -20.72 | -9.1 | -3.59 | -3.78 | |
| PFCF ratio | -9.93 | -18.05 | -8.95 | -3.54 | -3.69 | |
| P/B Ratio | 3.6K | 2.78 | 2.25 | 0.48 | 0.6 | |
| PTB ratio | 3.6K | 2.78 | 2.25 | 0.48 | 0.6 | |
| EV to sales | 0 | 12.27 | 9.27 | 2.71 | 2.65 | |
| Enterprise value over EBITDA | 87.99 | -20.91 | -7.11 | -0.79 | -3.33 | |
| EV to operating cash flow | -10.24 | -13.64 | -6.13 | -1.16 | -2.5 | |
| EV to free cash flow | -9.93 | -11.89 | -6.03 | -1.14 | -2.44 | |
| Earnings yield | 0 | -0.04 | -0.1 | -0.6 | -0.23 | |
| Free cash flow yield | -0.1 | -0.06 | -0.11 | -0.28 | -0.27 | |
| Debt to equity | 0.54 | 0.43 | 0.57 | 0.46 | 0.48 | |
| Debt to assets | 0.35 | 0.3 | 0.36 | 0.32 | 0.32 | |
| Net debt to EBITDA | -0.03 | 10.84 | 3.44 | 1.65 | 1.71 | |
| Current ratio | 7.55 | 4.77 | 4.08 | 1.97 | 1.89 | |
| Interest coverage | 0 | -164.1 | -110.53 | -205.88 | -112.67 | |
| Income quality | 0 | 1.29 | 1.06 | 0.99 | 1.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 1 | 0.79 | 1.88 | 0.62 | |
| Research and developement to revenue | 0 | 0.38 | 0.4 | 0.75 | 0.16 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.4 | 0.45 | |
| Capex to operating cash flow | 0.03 | 0.15 | 0.02 | 0.02 | 0.03 | |
| Capex to revenue | 0 | -0.13 | -0.03 | -0.04 | -0.03 | |
| Capex to depreciation | -0.27 | -1.33 | -0.24 | -0.15 | -0.21 | |
| Stock based compensation to revenue | 0 | 0.64 | 0.33 | 0.63 | 0.02 | |
| Graham number | 0 | 2.46 | 3.13 | 6.72 | 2.6 | |
| ROIC | 0 | 0.4 | 0.49 | -0.89 | -0.25 | |
| Return on tangible assets | 0 | -0.07 | -0.15 | -0.33 | -0.17 | |
| Graham Net | 0 | 1.12 | 0.72 | 0.18 | -0.06 | |
| Working capital | 467.15K | 382.26M | 309.79M | 198.1M | 144.28M | |
| Tangible asset value | 391.26K | 388.1M | 329.44M | 262.43M | 189.67M | |
| Net current asset value | 326.42K | 317.55M | 222.2M | 106.7M | 38.93M | |
| Invested capital | 0.03 | 0.08 | 0.22 | 0.12 | 0.14 | |
| Average receivables | 12.51M | 13.29M | 32.1M | 41.72M | 44.24M | |
| Average payables | 21.83M | 22.35M | 56.79M | 92.38M | 101.38M | |
| Average inventory | 14.58M | 16.74M | 34.89M | 38.96M | 42.89M | |
| Days sales outstanding | 0 | 41.36 | 62.81 | 113.97 | 46.14 | |
| Days payables outstanding | 0 | 82.76 | 128.31 | 158.58 | 112.21 | |
| Days of inventory on hand | 0 | 61.95 | 67.65 | 56.93 | 57.05 | |
| Receivables turnover | 0 | 2.18 | 1.43 | 0.79 | 1.95 | |
| Payables turnover | 0 | 1.09 | 0.7 | 0.57 | 0.8 | |
| Inventory turnover | 0 | 1.45 | 1.33 | 1.58 | 1.58 | |
| ROE | 0 | -0.1 | -0.23 | -0.29 | -0.14 | |
| Capex per share | -0.02 | -0.03 | -0.01 | -0.01 | -0.01 |
SMFR Frequently Asked Questions
What is Sema4 Holdings Corp. stock symbol ?
Sema4 Holdings Corp. is a US stock , located in Stamford of Ct and trading under the symbol SMFR
Is Sema4 Holdings Corp. buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $2.63. The lowest prediction is $1 and the highest is $3.5
What is SMFR stock prediction ?
What is Sema4 Holdings Corp. stock quote today ?
Sema4 Holdings Corp. stock price is $- today.
Is Sema4 Holdings Corp. stock public?
Yes, Sema4 Holdings Corp. is a publicly traded company.
Company Profile
- Volume Average 2.01M
- Market Capitalization 246.37M
- Employee 1.2K
- CEO Mr. Jason Ryan
- Headquarters Stamford,CT,US
- IPO Date 2020-11-04
-
Website
https://www.sema4.com 
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
